Ropes & Gray Advised Tanabe Pharma Corporation in the $2.5 Billion Sale of Global Rights to its RADICAVA Business to Shionogi

Ropes & Gray advised Tanabe Pharma Corporation, a Bain Capital portfolio company, in the sale of global rights to RADICAVA, a leading therapy for amyotrophic lateral sclerosis (ALS), to Japanese pharmaceutical company Shionogi. Under the agreement, which was announced on December 22, Shionogi will pay $2.5 billion in upfront consideration to Tanabe Pharma. The transaction is expected to close in the second quarter of 2026, subject to customary regulatory approvals.

The Ropes & Gray team was led by life sciences transactions partners Ray Grant and Arthur Mok, mergers & acquisitions partner Michael Brueck and IP transactions partner Emily Karlberg and included private equity partners Tsuyoshi Imai and Ben Morris, tax partner David Saltzman, antitrust partners Mike McFalls and Ruchit Patel, life sciences partners Josh Oyster, Katherine Wang and Lincoln Tsang, health care partners Jamie Darch and David Peloquin, employment, executive compensation and benefits partner Ellen Sueda, litigation & enforcement partner Geoff Atkins, tax counsel Michael Mendel, employment, executive compensation and benefits counsel Sean Smith and health care counsel Elizabeth Whitkin.